[{"id":"f1f6b8e5-c84d-462b-b982-ad3644c8b216","acronym":"ILLUMINATE 204","url":"https://clinicaltrials.gov/study/NCT02644967","created_at":"2021-01-18T12:52:09.133Z","updated_at":"2024-07-02T16:36:06.121Z","phase":"Phase 2","brief_title":"A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma","source_id_and_acronym":"NCT02644967 - ILLUMINATE 204","lead_sponsor":"Idera Pharmaceuticals, Inc.","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF wild-type","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Yervoy (ipilimumab) • tilsotolimod (IMO-2125)"],"overall_status":"Completed","enrollment":" Enrollment 53","initiation":"Initiation: 12/01/2015","start_date":" 12/01/2015","primary_txt":" Primary completion: 02/01/2020","primary_completion_date":" 02/01/2020","study_txt":" Completion: 05/01/2021","study_completion_date":" 05/01/2021","last_update_posted":"2022-08-03"}]